'Our findings can reassure that individuals with prolonged COVID-19 symptoms who have not been vaccinated that they should do so.' 'COVID-19 vaccination both before and after having COVID-19 significantly decreased post–COVID-19 conditions for the circulating variants during the study period although vaccine effectiveness was low,' they wrote. The authors said the results suggest that COVID-19 vaccines are more effective against persistent symptoms when given before infection, although recipients of post-infection doses also had some protection. The most common symptoms were fatigue or muscle weakness, muscle pain, anxiety, impaired memory, sleep difficulties, and shortness of breath. Among those vaccinated only after infection (three studies), the DOR was 0.726, and VE was 27.4% (95% CI, 25.4% to 29.3%). The DOR was 0.647, and VE was 35.3% (95% CI, 32.3% to 38.1%) among those vaccinated only before contracting COVID-19 (four studies). The pooled diagnostic odds ratio (DOR) for long COVID was 0.708, with an estimated VE of 29.2% (95% CI, 27.5% to 30.8%). Among unvaccinated participants, the pooled prevalence of long COVID was 39.1%, compared with 37.6% among vaccine recipients. The 251,123 total participants had received at least one dose of Pfizer/BioNTech, Moderna, AstraZeneca, or Johnson & Johnson vaccine. The studies were from Israel, Italy, the United Kingdom, and the United States. In the study, published today in Antimicrobial Stewardship & Healthcare Epidemiology, a team led by University of Iowa researchers analyzed data from six observational studies on vaccine effectiveness (VE) against long COVID published from Dec 1, 2019, to Apr 27, 2022. Ī meta-analysis of six studies estimates that one dose or more of COVID-19 vaccine is 29% effective against symptoms persisting for at least 3 weeks after infection, or long COVID. While awaiting a resupply, patients and parents should talk with their healthcare provider about alternative ADHD drugs such as Ritalin, Concerta, and Strattera, Nidhi Kumar, MD, of Saint Peter's Healthcare System in New Jersey, told CBS News. The DEA is unlikely to raise those limits in 2023, DrugWatch reports. Getting a prescription also became easier in 2020, when the US government eased rules to allow Adderall prescribing during telehealth visits.Īdderall is a controlled substance and therefore highly regulated by the US government, and the Drug Enforcement Administration (DEA) maintains strict rules on maximum production to avoid patient abuse of the drug. Increased demandĭemand has also been rising for Adderall, with an increase of nearly 20% in 2021 over 2020. Teva, the leading manufacturer of Adderall for the US market, blamed the shortage on intermittent manufacturing delays due to ongoing worker shortages, according to the Wall Street Journal. Pharmacies, though, had begun reporting shortages of Adderall over the summer, when 64% reported difficulty obtaining the drug. Other manufacturers continue to produce amphetamine mixed salts, but there is not sufficient supply to continue to meet U.S. The US Food and Drug Administration (FDA) announced the shortage of Adderall in October: ' FDA is in frequent communication with all manufacturers of amphetamine mixed salts, and one of those companies, Teva, is experiencing ongoing intermittent manufacturing delays. The estimated prevalence of ADHD among college students is 11.6% among adults, the prevalence is 4.4%. Americans with attention-deficit hyperactivity disorder (ADHD) are struggling to find good alternatives to the stimulant Adderall, which has been in short supply this fall and will likely not be back in stock until early next year.Ībout 6 million US children aged 3 to 17 years have been diagnosed as having ADHD, and 62% take a medication to help them focus and control their behavior, according to the Centers for Disease Control and Prevention.

D amphetamine salt